BioNTech SE ADR(BNTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 4:01 PM ET (Korea 10/27 05:01)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -7.85 | Insider Own | 0.43% | Shs Outstand | 251.2M | Perf Week | -2.63% |
| Market Cap | 21.82B | Forward P/E | - | EPS next Y | -1.81% | Insider Trans | -44.27% | Shs Float | 250.1M | Perf Month | -11.84% |
| Enterprise Value | 5.29B | PEG | - | EPS next Q | 0.75 | Inst Own | 19.79% | Short Float | 1% | Perf Quarter | -6.05% |
| Income | -1.97B | P/S | 7.06 | EPS this Y | -15.51% | Inst Trans | -0.2% | Short Ratio | 2 | Perf Half Y | -14.89% |
| Sales | 3.09B | P/B | 1.07 | EPS next 5Y | 7.15% | ROA | -8.08% | Short Interest | 2.50M | Perf YTD | -8.76% |
| Book/sh | 80.82 | P/C | 1.29 | EPS past 3/5Y | - | ROE | -9.35% | 52W High | -29.95% ($124.00) | Perf Year | -17.79% |
| Cash/sh | 67.25 | P/FCF | 45.5 | Sales past 3/5Y | -43.74% 42.57% | ROIC | -9.54% | 52W Low | 9.23% ($79.52) | Perf 3Y | -10.12% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -395.95% | Gross Margin | 63.87% | Volatility(W/M) | 2.78% 3.15% | Perf 5Y | -69.9% |
| Dividend TTM | - | EV/Sales | 1.71 | Sales Y/Y TTM | -1.05% | Oper. Margin | -37.57% | ATR (14) | 3.15 | Perf 10Y | - |
| Dividend Ex-Date | 2022/6/2 | Quick Ratio | 7.8 | EPS Q/Q | -108.42% | Profit Margin | -63.55% | RSI (14) | 36.23 | Recom | 1.83 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.85 | Sales Q/Q | -58.46% | SMA20 | -6.4% ($92.8) | Beta | 1.27 | Target Price | $117.12 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/11/3 | SMA50 | -11.69% ($98.36) | Rel Volume | 1.12 | Prev Close | $88.11 |
| Employees | 7807 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -54.07% -33.16% | SMA200 | -10.85% ($97.43) | Avg Volume(3M) | 1.25M | Price | $86.86 |
| IPO | 2019/10/10 | Option/Short | Yes/Yes | Trades | 13179 | Volume | 1,406,761 | Change | -1.42% |
🧬 This is a German large-cap biotech company operating an mRNA-based vaccine and immunotherapy platform. Founded in 2008 by Uğur Şahin and Özlem Türeci, the company is headquartered in Mainz, Germany, and is focusing on expanding its cancer immunotherapy pipeline on the back of its mRNA COVID-19 vaccine revenue.
Over the past 1 year, on the lower side
30% below its 1-year high.
Traded about as much as usual. That is 112% of its average volume.
Next earnings report: November 3
8 days to go.
BNTX has a sound balance sheet but weak earning power
Of every $100 in sales, $37.57 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -15.5% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $706. Peers typically go for $906.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -69.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 19.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #12 of 594 in the industry
Based on market cap of $22B.
GMAB#9 Genmab ADR $27B PER 35.4 
ROIV#10 Roivant Sciences Ltd $26B PER - 
INCY#11 Incyte Corp $23B PER 14.4 BNTX#12 BioNTech SE ADR $22B PER - 
INSM#13 Insmed Inc $20B PER - 
FAQ
What kind of company is BNTX?
BNTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BNTX?
The market cap of BNTX is approximately $21.8B, ranking 568 within its sector.
What is the 52-week high and low for BNTX?
BNTX has recorded a 52-week high of $124.00 and a low of $79.52.
